zonampanel monohydrate
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2000 (NCT00044070)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate receptor ionotropic AMPAANTAGONIST
Glutamate receptor ionotropic AMPA antagonist
Competitive antagonist.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21- Mol. weight
- 331.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL119625 ↗
Also known as
- (2,3-dioxo-7-(1h-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl)acetic acid monohydrate
- ym872
- ym872
- ym872
- ym 872
- ym-872
- ym-872
- ym-872
- zonampanel
- zonampanel
- zonampanel monohydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00044057 | Phase 2 | Dec 1, 2000 | Astellas |
| NCT00044070 | Phase 2 | Dec 1, 2000 | Astellas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 1 | 2000 |
1 organizations
Page 1 / 1